AbbVie’s pending Allergan takeover moves closer after drug divestments
28-01-2020
AbbVie to acquire Allergan for $63bn
25-06-2019
Ascannio / Shutterstock.com
Trade unions and consumer groups have urged the Federal Trade Commission (FTC) to intervene in the planned $63 billion merger of drugmakers AbbVie and Allergan, arguing it would “substantially harm competition”.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
AbbVie, Allergan, US Federal Trade Commission, FTC, antitrust, competition, brazikumab, divestiture, rebate walls, merger
